Palo Alto-based public benefit corporation co-founded in 2020 by neuroscientist Matthew Baggott and Luke Pustejovsky, developing novel MDMA-like entactogens and psychedelics as medicines. It uses machine learning and targeted assays to identify compounds with improved effectiveness, tolerability and safety for anxiety, depression and stress-related disorders, and has received US patents for novel MDMA-derivative compounds.